Evaluation of acetylcholinesterase in an animal model of mania induced by d-amphetamine

Psychiatry Research

Volumn 209, Issue 2, 2013, Pages 229-234

  Varela, Roger B ^a   Valvassori, Samira S ^a   Lopes Borges, Jéssica ^a   Fraga, Daiane B ^a   Resende, Wilson R ^a   Arent, Camila O ^a   Zugno, Alexandra I ^a   Quevedo, João ^a  

^a UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

Author keywords

Acetylcholinesterase; Animal model of mania; D Amphetamine; Lithium; Valproate

Indexed keywords

ACETYLCHOLINESTERASE; DEXAMPHETAMINE; LITHIUM SALT; MOOD STABILIZER; SODIUM CHLORIDE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; ENZYME ACTIVITY; HIPPOCAMPUS; LOCOMOTION; MALE; MANIA; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; WISTAR RAT;

ACETYLCHOLINESTERASE; ANIMAL MODEL OF MANIA; D-AMPHETAMINE; LITHIUM; VALPROATE;

ACETYLCHOLINESTERASE; ANALYSIS OF VARIANCE; ANIMALS; ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; LITHIUM COMPOUNDS; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR; VALPROIC ACID;

EID: 84883231614     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.11.021     Document Type: Article

References (69)

1. Andreazza A.C., Shao L., Wang J.F., Young L.T. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Archives of General Psychiatry 2010, 67:360-368.
2. Bhalla, P., Chadha, V.D., Dhawan, D.K., 2007. Effectiveness of zinc in modulating lithium induced biochemical and behavioral changes in rat brain. Cellular and Molecular Neurobiology 27, 595-607.
3. Barros D.M., Izquierdo L.A., Medina J.H., Izquierdo I. Bupropion and sertraline enhance retrieval of recent and remote long-term memory in rats. Behavioural Pharmacology 2002, 13:215-220.
4. Bechara A., Damasio H., Damasio A.R., Lee G.P. Different contributions of the human amygdala and ventromedial prefrontal cortex to decision-making. Journal of Neuroscience 1999, 19:5473-5481.
5. Berk M., Dodd S., Kauer-Sant'anna M., Malhi G.S., Bourin M., Kapczinski F., Norman T. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatrica Scandinavica 2007, 434:41-49.
6. Bonaccorso S., Meltzer H.Y., Li Z., Dai J., Alboszta A.R., Ichikawa J. SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Neuropsychopharmacology 2002, 27:430-441.
7. Brady A.E., Jones C.K., Bridges T.M., Kennedy J.P., Thompson A.D., Heiman J.U., Breininger M.L., Gentry P.R., Yin H., Jadhav S.B., Shirey J.K., Conn P.J. Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine induced hyperlocomotor activity in rats. Journal of Pharmacology and Experimental Therapeutics 2008, 327:941-953.
8. Bymaster F.P., Felder C.C. Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents. Molecular Psychiatry 2002, 7(Suppl 1):S57-63.
9. Cai N.S., McCoy M.T., Ladenheim B., Lyles J., Ali S.F., Cadet J.L. Serial analysis of gene expression in the rat striatum following methamphetamine administration. Annals of the New York Academy of Sciences 2006, 1074:13-30.
10. Camarasa J., Ratés S.G., Pubill D., Escubedo E. The involvement of nicotinic receptor subtypes in the locomotor activity and analgesia induced by methamphetamine in mice. Behavioural Pharmacology 2009, 20:623-630.
11. Cannon D.M., Carson R.E., Nugent A.C., Eckelman W.C., Kiesewetter D.O., Williams J., Rollis D., Drevets M., Gandhi S., Solorio G., Drevets W.C. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Archives of General Psychiatry 2006, 63:741-747.
12. Chen G., Zeng W.Z., Yuan P.X., Huang L.D., Jiang Y.M., Zhao Z.H., Manji H.K. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. Journal of Neurochemistry 1999, 72:879-882.
13. Chen R.W., Chuang D.M. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. Journal of Biological Chemistry 1999, 274:6039-6042.
14. Chuang D.M., Wang Z., Chiu C.T. GSK-3 as a target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke. Frontiers in Molecular Neuroscience 2011, 4:15.
15. Cummings J.L. Cholinesterase inhibitors: a new class of psychotropic compounds. American Journal of Psychiatry 2000, 157:4-15.
16. da-Rosa D.D., Valvassori S.S., Steckert A.V., Arent C.O., Ferreira C.L., Lopes-Borges J., Varela R.B., Mariot E., Dal-Pizzol F., Andersen M.L., Quevedo J. Differences between dextroamphetamine and methamphetamine: behavioral changes and oxidative damage in brain of Wistar rats. Journal of Neural Transmission 2012, 119:31-38.
17. Delgado E.H., Streck E.L., Quevedo J.L., Dal-Pizzol F. Mitochondrial respiratory dysfunction and oxidative stress after chronic malathion exposure. Neurochemical Research 2006, 31:1021-1025.
18. Di Chiara G., Morelli M., Consolo S. Modulatory functions of neurotransmitters in the striatum: ACh/dopamine/NMDA interactions. Trends in Neurosciences 1994, 17:228-233.
19. Digby G.J., Noetzel M.J., Bubser M., Utley T.J., Walker A.G., Byun N.E., Lebois E.P., Xiang Z., Sheffler D.J., Cho H.P., Davis A.A., Nemirovsky N.E., Mennenga S.E., Camp B.W., Bimonte-Nelson H.A., Bode J., Italiano K., Morrison R., Daniels J.S., Niswender C.M., Olive M.F., Lindsley C.W., Jones C.K., Conn P.J. Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models. Journal of Neuroscience 2012, 32:8532-8544.
20. Eleuteri S., Monti B., Brignani S., Contestabile A. Chronic dietary administration of valproic acid protects neurons of the rat nucleus basalis magnocellularis from ibotenic acid neurotoxicity. Neurotoxicity Research 2009, 15:127-132.
21. Ellman G.I., Courtney K.D., Andres V., Feather-Stone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical Pharmacology 1961, 7:88-95.
22. Ezz H.S., Khadrawy Y.A., Noor N.A. The neuroprotective effect of curcumin and Nigella sativa oil against oxidative stress in the pilocarpine model of epilepsy: a comparison with valproate. Neurochemical Research 2011, 36:2195-2204.
23. Fischer H.S., Zernig G., Schatz D.S., Humpel C., Saria A. MDMA ('ecstasy') enhances basal acetylcholine release in brain slices of the rat striatum. European Journal of Neuroscience 2000, 12:1385-1390.
24. Fortunato J.J., Agostinho F.R., Réus G.Z., Petronilho F.C., Dal-Pizzol F., Quevedo J. Lipid peroxidative damage on malathion exposure in rats. Neurotoxicity Research 2006, 9:23-28.
25. Frey B.N., Valvassori S.S., Réus G.Z., Martins M.R., Petronilho F.C., Bardini K., Dal-Pizzol F., Kapczinski F., Quevedo J. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. Journal of Psychiatry and Neuroscience 2006, 31:326-332.
26. Frey B.N., Andreazza A.C., Ceresér K.M., Martins M.R., Valvassori S.S., Réus G.Z., Quevedo J., Kapczinski F. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sciences 2006, 79:281-286.
27. Friedman J.I. Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology 2004, 174:45-53.
28. Geoffroy M., Tvede K., Christensen A.V., Schou J.S. The effect of imipramine and lithium on "learned helplessness" and acetylcholinesterase in rat brain. Pharmacology, Biochemistry and Behavior 1991, 38:93-97.
29. Gibbons A.S., Scarr E., McLean C., Sundram S., Dean B. Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. Journal of Affective Disorders 2009, 116:184-191.
30. Gould T.J., Keith R.A., Bhat R.V. Differential sensitivity to lithium's reversal of amphetamine-induced open-field activity in two inbred strains of mice. Behavioural Brain Research 2001, 118:95-105.
31. Gudelsky G.A., Yamamoto B.K. Actions of 3,4-methylenedioxymethamphetamine (MDMA) on cerebral dopaminergic, serotonergic and cholinergic neurons. Pharmacology, Biochemistry and Behavior 2007, 90:198-207.
32. Heidbreder C.A., Shippenberg T.S. Evidence for an involvement of muscarinic cholinergic systems in the induction but not expression of behavioral sensitization to cocaine. Synapse 1996, 24:182-192.
33. Ikemoto K., Kitahama K., Jouvet A., Arai R., Nishimura A., Nishi K., Nagatsu I. Demonstration of l-dopa decarboxylating neurons specific to human striatum. Neuroscience Letters 1997, 232:111-114.
34. Jing P., Jin Q., Wu J., Zhang X.J. GSK3beta mediates the induced expression of synaptic acetylcholinesterase during apoptosis. Journal of Neurochemistry 2008, 104:409-419.
35. Jones C.K., Shannon H.E. Effects of scopolamine in comparison with apomorphine and phencyclidine on prepulse inhibition in rats. European Journal of Pharmacology 2000, 391:105-112.
36. Lehmann J., Langer S.Z. The striatal cholinergic interneuron: synaptic target of dopaminergic terminals?. Neuroscience 1983, 10:1105-1120.
37. Levey A.I. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sciences 1993, 52:441-448.
38. Lowry O.H., Rosebough N.G., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry 1951, 193:265-275.
39. Machado-Vieira R., Zarate C.A. Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. Depression and Anxiety 2011, 28:267-281.
40. Mark G.P., Shabani S., Dobbs L.K., Hansen S.T. Cholinergic modulation of mesolimbic dopamine function and reward. Physiology & Behavior 2011, 104:76-81.
41. Marmol F. Lithium: bipolar disorder and neurodegenerative diseases. Possible cellular mechanisms of the therapeutic effects of lithium. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2008, 32:1761-1771.
42. Martinez D., Slifstein M., Broft A., Mawlawi O., Hwang D.R., Huang Y., Cooper T., Kegeles L., Zarahn E., Abi-Dargham A., Haber S.N., Laruelle M. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. Journal of Cerebral Blood Flow & Metabolism 2003, 23:285-300.
43. Martinowich K., Schloesser R.J., Manji H.K. Bipolar disorder: from genes to behavior pathways. Journal of Clinical Investigation 2009, 119:726-736.
44. Müller-Oerlinghausen B., Berghöfer A., Bauer M. Bipolar disorder. Lancet 2002, 359:241-247.
45. Mura A., Jackson D., Manley M.S., Young S.J., Groves P.M. Aromatic l-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous l-DOPA to dopamine. Brain Research 1995, 704:51-60.
46. Nair S.G., Gudelsky G.A. Protein kinase C inhibition differentially affects 3,4-methylenedioxymethamphetamine-induced dopamine release in the striatum and prefrontal cortex of the rat. Brain Research 2004, 1013:168-173.
47. Ong D., Walterfang M., Malhi G.S., Styner M., Velakoulis D., Pantelis C. Size and shape of the caudate nucleus in individuals with bipolar affective disorder. Australian and New Zealand Journal of Psychiatry 2012, 46:340-351.
48. Porritt M.J., Batchelor P.E., Hughes A.J., Kalnins R., Donnan G.A., Howells D.W. New dopaminergic neurons in Parkinson's disease striatum. Lancet 2000, 356:44-45.
49. Quiroz J.A., Singh J., Gould T.D., Denicoff K.D., Zarate C.A., Manji H.K. Emerging experimental therapeutics for bipolar disorder: clues from the molecular pathophysiology. Molecular Psychiatry 2004, 9:756-776.
50. Réus G.Z., Valvassori S.S., Nuernberg H., Comim C.M., Stringari R.B., Padilha P.T., Leffa D.D., Tavares P., Dagostim G., Paula M.M., Andrade V.M., Quevedo J. DNA damage after acute and chronic treatment with malathion in rats. Journal of Agricultural and Food Chemistry 2008, 56:7560-7565.
51. Robinson T.E., Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. Journal of Neuroscience 1997, 17:8491-8497.
52. Rocchi P., Tonelli R., Camerin C., Purgato S., Fronza R., Bianucci F., Guerra F., Pession A., Ferreri A.M. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncology Reports 2005, 13:1139-1144.
53. Rónai A.Z., Vizi S.E. The effect of lithium treatment on the acetylcholine content of rat brain. Biochemical Pharmacology 1975, 24:1819-1820.
54. Scarr E., Dean B. Role of the cholinergic system in the pathology and treatment of schizophrenia. Expert Review of Neurotherapeutics 2009, 9:73-86.
55. Scatton B., Simon H., Le Moal M., Bischoff S. Origin of dopaminergic innervation of the rat hippocampal formation. Neuroscience Letters 1980, 18:125-131.
56. Schilter B., Nöldner M., Chatterjee S.S., Honegger P. Anticonvulsant drug toxicity in rat brain cell aggregate cultures. Toxicology in Vitro 1995, 9:381-386.
57. Sperling L.E., Steinert G., Boutter J., Landgraf D., Hescheler J., Pollet D., Layer P.G. Characterisation of cholinesterase expression during murine embryonic stem cell differentiation. Chemico-Biological Interactions 2008, 175:156-160.
58. Steckert A.V., Valvassori S.S., Mina F., Lopes-Borges J., Varela R.B., Kapczinski F., Dal-Pizzol F., Quevedo J. Protein kinase C and oxidative stress in an animal model of mania. Current Neurovascular Research 2012, 9:47-57.
59. Townsend J.D., Bookheimer S.Y., Foland-Ross L.C., Moody T.D., Eisenberger N.I., Fischer J.S., Cohen M.S., Sugar C.A., Altshuler L.L. Deficits in inferior frontal cortex activation in euthymic bipolar disorder patients during a response inhibition task. Bipolar Disorders 2012, 14:442-450.
60. Tzavara E.T., Bymaster F.P., Davis R.J., Wade M.R., Perry K.W., Wess J., McKinzie D.L., Felder C., Nomikos G.G. M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. FASEB Journal 2004, 18:1410-1412.
61. Valvassori S.S., Rezin G.T., Ferreira C.L., Moretti M., Gonçalves C.L., Cardoso M.R., Streck E.L., Kapczinski F., Quevedo J. Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. Journal of Psychiatric Research 2010, 44:903-909.
62. Wada A. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. Journal of Pharmacological Sciences 2009, 110:14-28.
63. Weathers J.D., Stringaris A., Deveney C.M., Brotman M.A., Zarate C.A., Connolly M.E., Fromm S.J., LeBourdais S.B., Pine D.S., Leibenluft E. A developmental study of the neural circuitry mediating motor inhibition in bipolar disorder. American Journal of Psychiatry 2012, 169:633-641.
64. Wolfe J., Granholm E., Butters N., Saunders E., Janowsky D. Verbal memory deficits associated with major affective disorders: a comparison of unipolar and bipolar patients. Journal of Affective Disorders 1987, 13:83-92.
65. Womer F.Y., Kalmar J.H., Wang F., Blumberg H.P. A ventral prefrontal-amygdala neural system in bipolar disorder: a view from neuroimaging research. Acta Neuropsychiatrica 2009, 21:228-238.
66. Yatham L.N., Liddle P.F., Lam R.W., Shiah I.S., Lane C., Stoessl A.J., Sossi V., Ruth T.J. PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. American Journal of Psychiatry 2002, 159:1718-1723.
67. Yasuda R.P., Ciesla W., Flores L.R., Wall S.J., Li M., Satkus S.A., Weisstein J.S., Spagnola B.V., Wolfe B.B. Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. Molecular Pharmacology 1993, 43:149-157.
68. Yeomans J.S. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 1995, 12:3-16.
69. Zarate C.A., Singh J., Manji H.K. Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biological Psychiatry 2006, 59:1006-1020.